RPS6KA2 and Parkinson disease: For example, the top-scoring compounds TAE684, dovitinib, ruxolitinib, and fedratinib are observed to bind RPS6KA1 (Fig. 5a and Table 1), a component of a microglial signature59 with a potential role in AD as identified by previous epigenetic studies60, and RPS6KA2, a gene involved in Neurotrophin signaling61 with previous reports of association with Parkinson’s Disease in GWAS studies62.